Lupus Skin Is Primed for IL-6 Inflammatory Responses Through a Keratinocyte-Mediated Autocrine Type I Interferon Loop

Overview

Journal J Invest Dermatol

Publisher Elsevier

Specialty Dermatology

Date 2016 Sep 21

PMID 27646883

Citations 57

Authors

Jasmine N Stannard

Tamra J Reed

Emily Myers

Lori Lowe

Mrinal K Sarkar

Xianying Xing

Johann E Gudjonsson

J Michelle Kahlenberg

Affiliations

Soon will be listed here.

Abstract

Cutaneous lupus erythematosus is a disfiguring and common manifestation in systemic lupus erythematosus, and the etiology of this predisposition for cutaneous inflammation is unknown. Here, we sought to examine the keratinocyte as an important source of IL-6 and define the mechanism for its increased production in cutaneous lupus erythematosus. Evaluation of discoid and subacute cutaneous lupus erythematosus lesions showed significant epidermal up-regulation of IL-6 compared with control via real-time PCR and immunohistochemistry. Keratinocytes from unaffected skin of lupus patients produced significantly more IL-6 compared with healthy control subjects after exposure to toll-like receptor 2, 3, or 4 agonists or exposure to UVB radiation. Pretreatment with type I interferons (IFN-α and IFN-κ) increased IL-6 production by control keratinocytes, and type I IFN blockade decreased IL-6 secretion by lupus keratinocytes. Secretion of keratinocyte-specific IFN-κ was significantly increased after toll-like receptor 2 and UVB treatment in lupus keratinocytes, and neutralization of IFN-κ decreased IL-6 production by lupus keratinocytes. Thus, lupus keratinocytes are primed for IL-6 hyperproduction in a type I IFN-dependent manner. Increased production of IFN-κ by lupus keratinocytes drives this response, indicating that IFN-κ may play a pathogenic role in cutaneous lupus erythematosus and serve as a target for treatment.

Citing Articles

Lymphatic messengers: Non-antigen soluble mediators from diseased tissues to draining lymph nodes.

Howlader M, Rashighi M, Santambrogio L, Lu T Curr Opin Immunol. 2025; 93:102536.

PMID: 39914124 PMC: 11885046. DOI: 10.1016/j.coi.2025.102536.

Increasing evidence for the pathogenic role of keratinocytes in lupus.

Klein B, Billi A, Kahlenberg J Cell Mol Immunol. 2025; 22(3):333-335.

PMID: 39825106 PMC: 11868540. DOI: 10.1038/s41423-024-01254-7.

Keratinocytes - Amplifiers of Immune Responses in Systemic Lupus Erythematosus.

Klein B, Nguyen N, Moallemian R, Kahlenberg J Curr Rheumatol Rep. 2024; 27(1):1.

PMID: 39570551 DOI: 10.1007/s11926-024-01168-3.

Spatial Transcriptomics in Inflammatory Skin Diseases Using GeoMx Digital Spatial Profiling: A Practical Guide for Applications in Dermatology.

Cho C, Haddadi N, Kidacki M, Woodard G, Shakiba S, Yildiz-Altay U JID Innov. 2024; 5(1):100317.

PMID: 39559817 PMC: 11570843. DOI: 10.1016/j.xjidi.2024.100317.

How underappreciated autoinflammatory (innate immunity) mechanisms dominate disparate autoimmune disorders.

Abacar K, Macleod T, Direskeneli H, McGonagle D Front Immunol. 2024; 15:1439371.

PMID: 39372419 PMC: 11449752. DOI: 10.3389/fimmu.2024.1439371.

References

Chun H, Chung J, Kim H, Yun J, Jeon J, Ye Y . Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol. 2007; 27(5):461-6. DOI: 10.1007/s10875-007-9104-0. View

Kuhn A, Sontheimer R . Cutaneous lupus erythematosus: molecular and cellular basis of clinical findings. Curr Dir Autoimmun. 2008; 10:119-40. DOI: 10.1159/000131451. View

LaFleur D, Nardelli B, Tsareva T, Mather D, Feng P, Semenuk M . Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem. 2001; 276(43):39765-71. DOI: 10.1074/jbc.M102502200. View

Kadowaki N, Liu Y . Natural type I interferon-producing cells as a link between innate and adaptive immunity. Hum Immunol. 2002; 63(12):1126-32. DOI: 10.1016/s0198-8859(02)00751-6. View

Cash H, Relle M, Menke J, Brochhausen C, Jones S, Topley N . Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol. 2009; 37(1):60-70. DOI: 10.3899/jrheum.090194. View

Reiser J, Hurst J, Voges M, Krauss P, Munch P, Iftner T . High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol. 2011; 85(21):11372-80. PMC: 3194958. DOI: 10.1128/JVI.05279-11. View

Kahlenberg J, Thacker S, Berthier C, Cohen C, Kretzler M, Kaplan M . Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol. 2011; 187(11):6143-56. PMC: 3221936. DOI: 10.4049/jimmunol.1101284. View

Absher D, Li X, Waite L, Gibson A, Roberts K, Edberg J . Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations. PLoS Genet. 2013; 9(8):e1003678. PMC: 3738443. DOI: 10.1371/journal.pgen.1003678. View

Abdulahad D, Westra J, Reefman E, Zuidersma E, Bijzet J, Limburg P . High mobility group box1 (HMGB1) in relation to cutaneous inflammation in systemic lupus erythematosus (SLE). Lupus. 2013; 22(6):597-606. DOI: 10.1177/0961203313483377. View

10.

Szepietowski J, Nilganuwong S, Wozniacka A, Kuhn A, Nyberg F, van Vollenhoven R . Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum. 2013; 65(10):2661-71. DOI: 10.1002/art.38091. View

11.

Kirchner M, Sonnenschein A, Schoofs S, Schmidtke P, Umlauf V, Mannhardt-Laakmann W . Surface expression and genotypes of Toll-like receptors 2 and 4 in patients with juvenile idiopathic arthritis and systemic lupus erythematosus. Pediatr Rheumatol Online J. 2013; 11(1):9. PMC: 3626865. DOI: 10.1186/1546-0096-11-9. View

12.

Wenzel J, Worenkamper E, Freutel S, Henze S, Haller O, Bieber T . Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol. 2005; 205(4):435-42. DOI: 10.1002/path.1721. View

13.

Pivarcsi A, Bodai L, Rethi B, Kenderessy-Szabo A, Koreck A, Szell M . Expression and function of Toll-like receptors 2 and 4 in human keratinocytes. Int Immunol. 2003; 15(6):721-30. DOI: 10.1093/intimm/dxg068. View

14.

Furie R, Khamashta M, Merrill J, Werth V, Kalunian K, Brohawn P . Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017; 69(2):376-386. PMC: 5299497. DOI: 10.1002/art.39962. View

15.

Mellor-Pita S, Citores M, Castejon R, Yebra-Bango M, Tutor-Ureta P, Rosado S . Monocytes and T lymphocytes contribute to a predominance of interleukin 6 and interleukin 10 in systemic lupus erythematosus. Cytometry B Clin Cytom. 2009; 76(4):261-70. DOI: 10.1002/cyto.b.20468. View

16.

Wozniacka A, Lesiak A, Boncela J, Smolarczyk K, McCauliffe D, Sysa-Jedrzejowska A . The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus. Br J Dermatol. 2008; 159(5):1124-30. DOI: 10.1111/j.1365-2133.2008.08804.x. View

17.

Makol A, Gibson L, Michet C . Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis. J Clin Rheumatol. 2012; 18(2):92-5. DOI: 10.1097/RHU.0b013e31823ecd73. View

18.

Baechler E, Batliwalla F, Karypis G, Gaffney P, Ortmann W, Espe K . Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003; 100(5):2610-5. PMC: 151388. DOI: 10.1073/pnas.0337679100. View

19.

Coit P, Jeffries M, Altorok N, Dozmorov M, Koelsch K, Wren J . Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naïve CD4+ T cells from lupus patients. J Autoimmun. 2013; 43:78-84. PMC: 3790645. DOI: 10.1016/j.jaut.2013.04.003. View

20.

Illei G, Shirota Y, Yarboro C, Daruwalla J, Tackey E, Takada K . Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010; 62(2):542-52. PMC: 3057537. DOI: 10.1002/art.27221. View